Efficacy of human papillomavirus-based screen-and-treat for cervical cancer prevention among HIV-infected womens

AIDS

Volumn 24, Issue 16, 2010, Pages 2553-2561

  Kuhn, Louise ^a,b   Wang, Chunhui ^c   Tsai, Wei Yann ^b   Wright, Thomas C ^c   Denny, Lynette ^d  

^a Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^b University of Cape Town ^*  (United States)

^c NONE   (United States)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Cervical cancer; Human papillomavirus; Prevention; Screening; South Africa

Indexed keywords

ACETIC ACID; VIRUS DNA;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PREVENTION; CANCER SCREENING; CLINICAL TRIAL; COLPOSCOPY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYOTHERAPY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT DURATION; TREATMENT FAILURE; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

ADULT; AGED; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; CRYOTHERAPY; DNA, VIRAL; FEMALE; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; SOUTH AFRICA; UTERINE CERVICAL NEOPLASMS;

EID: 78549296355     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833e163e     Document Type: Article

References (32)

1. Heard I. Prevention of cervical cancer in women with HIV. Curr Opin HIV AIDS 2009;4:68-73.
2. De Vuyst H, Lillo F, Broutet N, Smith JS. HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy. Eur J Cancer Prev 2008;17:545-554.
3. Mwanahamuntu MH, Sahasrabuddhe VV, Pfaendler KS, Mu- denda V, Hicks ML, VermundSH, eta/. Implementation of'see- and-treat' cervical cancer prevention services linked to HIV care in Zambia. AIDS 2009;23:N1-N5.
4. Pfaendler KS, Mwanahamuntu MH, Sahasrabuddhe VV, Mudenda V, Stringer JS, Parham GP. Management of cryo- therapy-ineligible women in a 'screen-and-treat' cervical cancer prevention program targeting HIV-infected women in Zambia: lessons from the field. Gynecol Oncol 2008;110: 402-407.
5. Denny L, Quinn M, Sankaranarayanan R. Screening for cervical cancer in developing countries. Vaccine 2006;24 Suppl 13:S71-S77.
6. Denny L. The prevention of cervical cancer in developing countries. BJOG 2005;112:1204-1212. (Pubitemid 43960915)
7. Denny L, Kuhn L, De Souza M, Pollack AE, Dupree W, Wright TC Jr. Screen-and-treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial. JAMA 2005;294:2173-2181.
8. Visual inspection with acetic acid for cervical-cancer screening: test qualities in a primary-care setting. University of Zimbabwe/JHPIEGO Cervical Cancer Project. Lancet 1999; 353:869-873.
9. Gaffikin L, Blumenthal PD, Emerson M, Limpaphayom K. Safety, acceptability, and feasibility of a single-visit approach to cervical-cancer prevention in rural Thailand: a demonstration project. Lancet 2003;361:814-820.
10. Sankaranarayanan R, Esmy PO, Rajkumar R, Muwonge R, Swaminathan R, Shanthakumari S, et al. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet 2007;370:398-406.
11. Blumenthal PD, Gaffikin L, Deganus S, Lewis R, Emerson M, Adadevoh S. Cervical cancer prevention: safety, acceptability, and feasibility of a single-visit approach in Accra, Ghana. Am J Obstet Gynecol 2007;196:407-408.
12. Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009;360:1385-1394.
13. Collett D. Modelling survival data in medical research. New York, USA: Chapman-Hall;1994.
14. Tebeu PM, Major AL, Mhawech P, Rapiti E. The recurrence of cervical intraepithelial neoplasia in HIV-positive women: a review of the literature. Int J STD AIDS 2006;17:507-511.
15. Massad LS, Fazzari MJ, Anastos K, Klein RS, Minkoff H, Jamieson DJ, et al. Outcomes after treatment of cervical intraepithelial neoplasia among women with HIV. J Low Genit Tract Dis 2007; 11:90-97.
16. Chirenje ZM, Rusakaniko S, Akino V, Munjoma M, Mlingo M. Effect of HIV disease in treatment outcome of cervical squa- mous intraepithelial lesions among Zimbabwean women. J Low Genit Tract Dis 2003; 7:16-21 .
17. Heard I, Potard V, Foulot H, Chapron C, Costagliola D, Kazatchkine MD. High rate of recurrence of cervical intrae- pithelial neoplasia after surgery in HIV-positive women. J Acquir Immune Defic Syndr 2005;39:412-418.
18. Harris TG, Burk RD, PalefskyJM, Massad LS, BangJY, Anastos K, et al. Incidence of cervical squamous intraepithelial lesions associated with HIV serostatus, CD4 cell counts, and human papillomavirus test results. JAMA 2005; 293:1471-1476.
19. Hawes SE, Critchlow CW, Faye Niang MA, Diouf MB, Diop A, Toure P, et al. Increased risk of high-grade cervical squamous intraepithelial lesions and invasive cervical cancer among African women with human immunodeficiency virus type 1 and 2 infections. J Infect Dis 2003;188:555-563.
20. Sahasrabuddhe VV, Mwanahamuntu MH, Vermund SH, Huh WK, Lyon MD, Stringer JS, Parham GP. Prevalence and distribution of HPV genotypes among HIV-infected women in Zambia. Br J Cancer 2007;96:1480-1483.
21. Womack SD, Chirenje ZM, Gaffikin L, Blumenthal PD, McGrath JA, Chipato T, et al. HPV-based cervical cancer screening in a population at high risk for HIV infection. Int J Cancer 2000; 85:206-210.
22. Singh DK, Anastos K, Hoover DR, Burk RD, Shi Q, Ngendahayo L, et al. Human papillomavirus infection and cervical cytology in HIV-infected and HIV-uninfected Rwandan women. J Infect Dis 2009;199:1851-1861.
23. Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008;26 Suppl 10:K1-K16.
24. de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, Bosch FX. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007; 7:453-459.
25. Sun XW, Ellerbrock TV, Lungu O, Chiasson MA, Bush TJ, Wright TC Jr. Human papillomavirus infection in human immunodeficiency virus-seropositive women. Obstet Gynecol 1995; 85:680-686.
26. Ahdieh L, Munoz A, Vlahov D, Trimble CL, Timpson LA, Shah K. Cervical neoplasia and repeated positivity of human papil- lomavirus infection in human immunodeficiency virus-seropo- sitive and -seronegative women. Am J Epidemiol 2000; 151 :1148-1157.
27. Kitchener H, Nelson L, Adams J, Mesher D, Sasieni P, Cubie H, et al. Colposcopy is not necessary to assess the risk to the cervix in HIV-positive women: an international cohort study of cervical pathology in HIV-1 positive women. Int J Cancer 2007; 121 :2484-2491 .
28. Zhang Q, Kuhn L, Denny LA, De SM, Taylor S, Wright TC Jr. Impact of utilizing p16INK4A immunohistochemistry on estimated performance of three cervical cancer screening tests. Int J Cancer 2007;120:351-356.
29. GageJC, Hanson VW, Abbey K, Dippery S, Gardner S, Kubota J, et al. Number of cervical biopsies and sensitivity of colposcopy. Obstet Gynecol 2006;108:264-272.
30. Minkoff H, Zhong Y, Burk RD, Palefsky JM, Xue X, Watts DH, et al. Influence of adherent and effective antiretroviral therapy use on human papillomavirus infection and squamous intrae- pithelial lesions in human immunodeficiency virus-positive women. J Infect Dis 2010;201:681-690.
31. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, Gordillo-Tobar A, Levin C, Mahe C, Wright TC. Cost-effectiveness of cervical- cancer screening in five developing countries. N Engl J Med 2005; 353:2158-2168.
32. Levin CE, SellorsJ, Shi JF, Ma L, Qiao YL, Ortendahl J, et al. Cost-effectiveness analysis of cervical cancer prevention based on a rapid human papillomavirus screening test in a high-risk region of China. Int J Cancer 2010;27:1404-1411.